A me-too strategy for me-too drugs

By DAVID E. WILLIAMS AstraZeneca appears set to follow Merck into the market for “bio-similars.” (See AstraZeneca may join generic rush.) Congress and the media tend to portray biosimilars are analogous to generic chemistry-based pharmaceuticals, and therefore believe that they...
January 4, 2009 in David E. Williams, Pharma | Permalink | Comments (1)